Strategic Intelligence: Rare Disease: Innovation, Investment, and Unmet Need
Summary
Rare disease is a large, structurally underserved market.Development activity is heavily weighted to oncology, but oncology is also the least mature part of the pipeline.
Dealmaking in rare disease has accelerated sharply, with 2026 already the biggest year on record for M&As.
Orphan drug designations keep climbing, but regulatory approval does not guarantee patients can actually get the drug.
Scope
- This report talks about the rare disease landscape, including where drug dveelopment is concentrated across therapy areas, indications, and modalities. Also, the most active companies in this field are highlighted and how they are building through M&As and licensing agreements, all while the regulatory and access environment is continuously evolving.
Reasons to Buy
- This report talks about the rare disease landscape, including where drug dveelopment is concentrated across therapy areas, indications, and modalities. Also, the most active companies in this field are highlighted and how they are building through M&As and licensing agreements, all while the regulatory and access environment is continuously evolving.
Table of Contents
- Executive Summary
- Introduction
- Rare Disease Overview
- Drug Development
- Case Studies
- Companies
- Regulatory
- Unmet Need and Access
- Key Takeaways
- Appendix:
- Abbreviations
- Related Reports
- Authors
- Contact Us
